TABLE 13-2.
Dosages for Common Injectable Sedatives, Analgesics, Preanesthetics, Anesthetics, and Antagonists Used in Ferrets
| Drug | Dosage | Use |
|---|---|---|
| Acepromazine | 0.2-0.5 mg/kg SC, IM | sedative |
| 0.1-0.25 mg/kg SC, IM | preanesthetic | |
| Atipamizole | 0.4 mg/kg IM | alpha-2 antagonist |
| Buprenorphine | 0.01 mg/kg SC, IM | analgesia |
| Butorphanol | 0.05-0.1 mg/kg SC, IM | analgesia |
| Diazepam | 1-2 mg/kg IM | sedative |
| Ketamine | 10-20 mg/kg IM | sedative |
| 30-60 mg/kg IM | anesthetic | |
| Ketamine/diazepam | 25-35 mg/kg (K), 2-3 mg/kg (D) IM | anesthetic |
| Ketamine/medetomidine | 5 mg/kg (K), 0.08 mg/kg (M) IM | anesthetic |
| Ketamine/medetomidine/butorphanol | 5 mg/kg (K), 0.08 mg (M), 0.1 mg/kg (B) IM | anesthetic |
| Ketamine/xylazine | 20-40 mg/kg (K), 1-4 mg/kg (X) IM | anesthetic |
| Medetomidine | 0.08-0.1 mg/kg IM | sedative |
| Medetomidine/butorphanol | 0.08 mg/kg (M), 0.1 mg/kg (B) IM | anesthetic |
| Naloxane | 0.04-1.0 mg/kg IV, IM, SC | opioid antagonist |
| Telazol | 12-22 mg/kg IM | anesthetic at higher dosage |
| Xylazine | 1 mg/kg SC, IM | sedative |
| Yohimbine | 0.5 mg/kg IM | alpha-2 antagonist |
Dosages acquired from Marini RP, Fox JG: Anesthesia, surgery, and biomethodology. In Fox JG, editor: Biology and Diseases of the Ferret, ed 2, Philadelphia, 1998, Lippincott Williams and Wilkins.
© 2009 Lippincott Williams and Wilkins
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.